Skip to main content
PMC home page
Immunology logoLink to Immunology
. 1993 May;79(1):64–68.

The SKW 6.4 line of human B lymphocytes specifically binds and responds to vasoactive intestinal peptide.

P P Cheng 1, S P Sreedharan 1, J L Kishiyama 1, E J Goetzl 1
PMCID: PMC1422037  PMID: 8509142

Abstract

Vasoactive intestinal peptide (VIP1-28) is a neuromediator recognized by high-affinity receptors on human lymphocytes, which inhibits T-cell proliferation and cytokine secretion, and suppresses immunoglobulin production by mitogen-stimulated mixed mononuclear leucocytes. The direct interactions of VIP1-28 with B cells were studied in the SKW 6.4 line of EBV-transformed human B cells, that express a mean (+/- SD) of 6116 +/- 969 receptors for [125I]VIP1-28 with a mean Kd of 59 nM, that decreases to 12 nM after exposure to phorbol 12-myristate 13-acetate (PMA). The secretion of IgM by SKW 6.4 B cells stimulated optimally with 100 ng/ml of PMA, but not unstimulated secretion of IgM, was suppressed significantly by 10(-12) M to 10(-9) M VIP1-28 and up to a mean maximum (+/- SD) of 40 +/- 2% by 10(-10) M VIP1-28. VIP1-28 elicited concomitant increases in intracellular cyclic AMP up to a mean maximum of 163% at 10(-10) M VIP1-28. The requirement for specific signal transduction by the occupied VIP receptors to inhibit IgM secretion was demonstrated by the lack of effect of VIP4-28 on both cyclic AMP concentration and IgM secretion, despite the equal affinity of binding of VIP4-28 and VIP1-28. The effects of VIP on immunoglobulin secretion by stimulated mixed mononuclear leucocytes thus may be due in part to a direct action on B cells.

Full text

PDF
64

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. De Lean A., Hancock A. A., Lefkowitz R. J. Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. Mol Pharmacol. 1982 Jan;21(1):5–16. [PubMed] [Google Scholar]
  2. Felten D. L., Felten S. Y., Carlson S. L., Olschowka J. A., Livnat S. Noradrenergic and peptidergic innervation of lymphoid tissue. J Immunol. 1985 Aug;135(2 Suppl):755s–765s. [PubMed] [Google Scholar]
  3. Finch R. J., Sreedharan S. P., Goetzl E. J. High-affinity receptors for vasoactive intestinal peptide on human myeloma cells. J Immunol. 1989 Mar 15;142(6):1977–1981. [PubMed] [Google Scholar]
  4. Goetzl E. J., Kodama K. T., Turck C. W., Schiogolev S. A., Sreedharan S. P. Unique pattern of cleavage of vasoactive intestinal peptide by human lymphocytes. Immunology. 1989 Apr;66(4):554–558. [PMC free article] [PubMed] [Google Scholar]
  5. Ishioka C., Yoshida A., Kimata H., Mikawa H. Vasoactive intestinal peptide stimulates immunoglobulin production and growth of human B cells. Clin Exp Immunol. 1992 Mar;87(3):504–508. doi: 10.1111/j.1365-2249.1992.tb03027.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Neil G. A., Blum A., Weinstock J. V. Substance P but not vasoactive intestinal peptide modulates immunoglobulin secretion in murine schistosomiasis. Cell Immunol. 1991 Jul;135(2):394–401. doi: 10.1016/0008-8749(91)90284-i. [DOI] [PubMed] [Google Scholar]
  7. O'Dorisio M. S., Shannon B. T., Fleshman D. J., Campolito L. B. Identification of high affinity receptors for vasoactive intestinal peptide on human lymphocytes of B cell lineage. J Immunol. 1989 May 15;142(10):3533–3536. [PubMed] [Google Scholar]
  8. Ottaway C. A. In vitro alteration of receptors for vasoactive intestinal peptide changes the in vivo localization of mouse T cells. J Exp Med. 1984 Oct 1;160(4):1054–1069. doi: 10.1084/jem.160.4.1054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ottaway C. A. Selective effects of vasoactive intestinal peptide on the mitogenic response of murine T cells. Immunology. 1987 Oct;62(2):291–297. [PMC free article] [PubMed] [Google Scholar]
  10. Said S. I. Vasoactive intestinal peptide. J Endocrinol Invest. 1986 Apr;9(2):191–200. doi: 10.1007/BF03348097. [DOI] [PubMed] [Google Scholar]
  11. Saiki O., Ralph P. Clonal differences in response to T cell replacing factor (TRF) for IgM secretion and TRF receptors in a human B lymphoblast cell line. Eur J Immunol. 1983 Jan;13(1):31–34. doi: 10.1002/eji.1830130108. [DOI] [PubMed] [Google Scholar]
  12. Stanisz A. M., Befus D., Bienenstock J. Differential effects of vasoactive intestinal peptide, substance P, and somatostatin on immunoglobulin synthesis and proliferations by lymphocytes from Peyer's patches, mesenteric lymph nodes, and spleen. J Immunol. 1986 Jan;136(1):152–156. [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES